PCSA — Processa Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1533743 ·
Last close
$1.73
Market Cap
$4.84M
52W High
$8.88
52W Low
$1.04
ADV30
139,355
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,336,138 | -3,265,494 | 2,069,562 | 196,325 | 2,386,903 |
| Mar 2026 | 0 | — | -3,331,214 | -3,377,179 | 4,520,974 | 1,691,043 | 1,980,093 |
| Dec 2025 | 0 | — | -3,701,889 | -3,358,938 | 7,813,567 | 5,536,955 | 2,236,253 |
| Sep 2025 | 0 | — | -3,488,843 | -3,436,573 | 7,584,576 | 6,308,420 | 1,750,978 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,971,522
Investing CF
$-1,164,000
Financing CF
$6,395,227
CapEx
—
Dividends Paid
—
Buybacks
$-320
EPS Diluted TTM
$-10.49
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-107,425,706
Inventory
—
Receivables
—
ST Investments
$472,003
EBIT TTM
$-12,858,084
Pretax Income TTM
$-13,438,184
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,988,505 | -13,563,834 | 7,813,567 | 2,236,253 | 5,577,314 | -11,385,195 |
| Dec 2024 | 0 | -12,051,206 | -11,850,118 | 3,229,289 | 1,533,118 | 1,696,171 | -11,245,042 |
| Dec 2023 | 0 | -11,457,061 | -11,121,520 | 5,786,643 | 797,484 | 4,989,159 | -8,063,346 |
| Dec 2022 | 0 | -20,257,288 | -27,424,229 | 8,619,851 | 1,149,110 | 7,470,741 | -9,605,143 |
TTM Snapshot
Revenues TTM
$-104,662
NetIncome TTM
$-13,438,184
OpCashFlow TTM
—
Assets (Latest)
$2,069,562
Forward EPS
$-3.75
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CNSY | CERENOME, INC. | $4.78M | $0.63 | — |
| CDT | CDT Equity Inc. | $4.93M | $0.36 | — |
| PULM | Pulmatrix, Inc. | $5.00M | $1.37 | — |
| LTRN | Lantern Pharma Inc. | $4.67M | $0.37 | — |
| CMND | Clearmind Medicine Inc. | $5.13M | $3.45 | — |
News headlines (Yahoo Finance, 1h cache)
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-11-05 13:00 · Yahoo
Processa Pharmaceuticals Announces Key Leadership Appointments
2026-11-04 13:00 · Yahoo
Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics
2026-10-29 12:00 · Yahoo
Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline
2026-07-29 14:33 · Yahoo
PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA
2026-07-29 11:30 · Yahoo
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
2026-01-12 14:15 · Yahoo
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-01-09 14:00 · Yahoo
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
2026-01-05 14:15 · Yahoo
Wall Street Set to Open Higher Thursday as Inflation Rises Less Than Expected; Jobless Claims Decline
2025-12-18 14:23 · Yahoo
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
2025-12-17 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.